Sunho Biologics (HKSE:02898) Cash, Cash Equivalents, Marketable Securities : HK$488.23 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Cash, Cash Equivalents, Marketable Securities?

Sunho Biologics's quarterly cash, cash equivalents, marketable securities increased from Dec. 2023 (HK$229.77 Mil) to Jun. 2024 (HK$532.67 Mil) but then stayed the same from Jun. 2024 (HK$532.67 Mil) to Dec. 2024 (HK$488.23 Mil).

Sunho Biologics's annual cash, cash equivalents, marketable securities increased from Dec. 2022 (HK$2.03 Mil) to Dec. 2023 (HK$229.77 Mil) and increased from Dec. 2023 (HK$229.77 Mil) to Dec. 2024 (HK$488.23 Mil).

Sunho Biologics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Sunho Biologics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Cash, Cash Equivalents, Marketable Securities Chart

Sunho Biologics Annual Data

Trend

Dec22

Dec23

Dec24

Cash, Cash Equivalents, Marketable Securities

2.03

229.77

488.23

Sunho Biologics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
Cash, Cash Equivalents, Marketable Securities	2.03	-	229.77	532.67	488.23

Sunho Biologics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Sunho Biologics (HKSE:02898) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Sunho Biologics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunho Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN

Website

http://www.sunho-bio.com.cn

Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

Executives

Sunho Fortune Investments Limited	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Zhang Feng	2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited	2101 Beneficial owner

Sunho Biologics Headlines

No Headlines